NCT05027074: A reported trial by Merck Sharp & Dohme LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05027074 |
|---|---|
| Title | A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 17, 2021 |
| Completion date | Oct. 30, 2024 |
| Required reporting date | Oct. 30, 2025, midnight |
| Actual reporting date | Sept. 23, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |